BI/Lilly’s Jardiance To Face Off With AstraZeneca’s Farxiga In CKD After EU Nod

 
• By Ayisha Sharma

The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.  

graphic illustration of kidneys
Chronic Kidney Disease Affects 850 Million People Worldwide • Source: Shutterstock

More from Genitourinary

More from Therapy Areas